Please login to the form below

Spark Therapeutics

This page shows the latest Spark Therapeutics news and features for those working in and with pharma, biotech and healthcare.

BioMarin and Spark Therapeutics.

Spark sputters on haemophilia A gene therapy safety scare

Spark sputters on haemophilia A gene therapy safety scare. Investors compare data unfavourably with BioMarin rival. ... Gene therapy developer Spark Therapeutics has seen around $1bn carved off its value after it emerged that two patients in its
Bluebird’s first gene therapy gets European fast track

recommendation, while Spark Therapeutics’gene therapy Luxturna looks set to gain CHMP recommendation by the end of 2018.
Pfizer enters late-stage haemophilia B gene therapy trial

Pfizer’s phase III programme will test the Spark Therapeutics-developed compound after it gathers safety and efficacy data of current factor IX prophylaxis replacement therapy as a lead-in study. ... We look forward to the opportunity to continue the
Axovant licenses another gene therapy as new strategy beds in

developed by Oxford BioMedica – and after Axovant hired former Spark Therapeutics ’exec Fraser Wright to bolt on expertise in the gene therapy sector.
UniQure’s starts pivotal haemophilia B gene therapy trial

UniQure has enrolled the first patient in its registration trial of haemophilia B gene therapy candidate AMT-061 as it tries to keep ahead of a rival project from Spark ... The start of the trial puts UniQure fractionally ahead of its main rival Spark

More from news
Approximately 9 fully matching, plus 15 partially matching documents found.

The European Medicines Agency: PRIME’d for access?

sales, and 6 are in the top 10 companies with Pfizer (with Spark Therapeutics), Novartis (by acquiring AveXis), Celgene (with Bluebird and through acquiring Juno Therapeutics), Sanofi, Roche and Merck all ... Those prices pale in comparison though when
Bluebird Bio: on the cusp of a gene therapy revolution

drugs, Novartis’Kymriah and Gilead/Kite’s Yescarta and Spark Therapeutics’gene therapy Luxturna all reaching the market last year. ... of a more stable adeno-associated virus (AAV) – which now forms the basis of Spark Therapeutics’drugs and, in
Health on instalment

For example, Luxturna maker Spark Therapeutics approached a commercial payer with a pay-for-performance option.
The rise of real-world evidence

Spark Therapeutics has a similar arrangement for its gene therapy. These agreements make real-world efficacy a requirement for full payment for a drug.
Deal Watch December 2016

and Bicycle Therapeutics at $1bn, and the Purdue Pharma-Exicure deal, at $790m. ... The size of the deals signed by AstraZeneca with Bicycle Therapeutics, by Spark with Selecta Biosciences and by Celgene with Evotec suggest that their technologies

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Industry appointments

Sigilon has already reached certain milestones for its Living Therapeutics product platform, including its Afibromer technology, which represents a new class of breakthrough implantable biomaterials. ... Vivaldi has more than 25 years’experience and

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Add my company

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....